Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics is a medical technology company with significant potential for growth and profitability in the sleep-disordered breathing market. While there is a need for additional financing in the near term, the company has a strong strategic investor and potential for accretive acquisitions to drive growth and improve profitability. Recent financial results have shown strong revenue growth and improved gross margins, although net losses widened due to a transition to a new distribution strategy. The company's recent partnership with SoundHealth and plans to expand their channel through both affiliation and ownership models highlight their commitment to growth. However, there may be some challenges in meeting operational efficiency and addressing potential share dilution as the company continues to invest in its operations and service its outstanding debt. Overall, we maintain our BUY rating and adjust our price target to $3.00 to account for a higher share count and potential risks, while considering the company's multi-billion-dollar market potential and favorable product positioning.

Bears say

Vivos Therapeutics is facing challenges in its transition from its VIP/dentist model to the sleep-center model, with lower revenue and higher expenses leading to a negative EPS estimate for FY26. However, the company's proprietary Vivos System offers a potential solution with limited treatment times and durable effects compared to the traditional CPAP treatment for sleep apnea, which affects over 30 million adults in the U.S. While there are risks to achieving its projected sales growth and price target, Vivos continues to work towards expanding its operations and gaining regulatory approvals, making it a potentially attractive long-term investment opportunity.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.